Key facts
- This page summarizes Robert M. Davis's Form 4 filing for Merck & Co., Inc. (MRK).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 15 Feb 2024, 16:01.
Robert M. Davis - 13 Feb 2024 Form 4 Insider Report for Merck & Co., Inc. (MRK)
- Reporting relationship
- Chairman, CEO & President, Director
- Issuer ticker
- MRK
- Reported as of
- 13 Feb 2024
- Net transaction value
- -$12,143,240
- SEC form
- 4
- Accepted by SEC
- 15 Feb 2024, 16:01:31 UTC
- Prior SEC filing
- 24 Jan 2024
- Next SEC filing
- 02 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly E. W. Grez as Attorney-in-Fact for Robert M. Davis
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert M. Davis filed Form 4 for Merck & Co., Inc. (MRK) on 15 Feb 2024.
Change
- Previous filing in this sequence was filed on 24 Jan 2024.
- Current net transaction value: -$12,143,240.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $3,128,118
- Shares
- +41,509
- Change %
- +12%
- Price
- $75.36
- Shares after
- 389,836
- Date
- 13 Feb 2024
- Ownership
- Direct
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $7,999,041
- Shares
- +108,491
- Change %
- +28%
- Price
- $73.73
- Shares after
- 498,327
- Date
- 13 Feb 2024
- Ownership
- Direct
MRK
transaction
Common Stock
Sale
- Transaction value
- $15,677,147
- Shares
- -124,676
- Change %
- -25%
- Price
- $125.74
- Shares after
- 373,651
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
MRK
transaction
Common Stock
Sale
- Transaction value
- $3,200,277
- Shares
- -25,324
- Change %
- -6.8%
- Price
- $126.37
- Shares after
- 348,327
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $6,268,598
- Shares
- +85,021
- Change %
- +24%
- Price
- $73.73
- Shares after
- 433,348
- Date
- 14 Feb 2024
- Ownership
- Direct
MRK
transaction
Common Stock
Sale
- Transaction value
- $10,661,574
- Shares
- -85,021
- Change %
- -20%
- Price
- $125.40
- Shares after
- 348,327
- Date
- 14 Feb 2024
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -41,509
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 83,020
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,509
- Exercise price
- $75.36
- Footnotes
- F4, F5
MRK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -108,491
- Change %
- -37%
- Price
- $0.000000
- Shares after
- 181,781
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 108,491
- Exercise price
- $73.73
- Footnotes
- F4, F6
MRK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -85,021
- Change %
- -47%
- Price
- $0.000000
- Shares after
- 96,760
- Date
- 14 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,021
- Exercise price
- $73.73
- Footnotes
- F4, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.2700 to $126.2600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.2650 to $126.525, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.0900 to $125.8200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
Footnote F5
The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
Footnote F6
The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.